melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the meta-analysis suggests that there is a significant association between ERCC2 Lys751Gln polymorphism and susceptibility to cutaneous melanoma.
|
23494240 |
2013 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The data from our study support the notion that only XPC and XPD genes are associated with melanoma susceptibility.
|
23436679 |
2013 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Thus, ERCC5 codon 1104 and ERCC2 codon 751 polymorphisms are independent prognostic factors in patients with cutaneous melanoma.
|
21390047 |
2011 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
On stratified analysis by tumor type, XPD Lys751Gln polymorphism was not associated with increased risk of non-melanoma skin cancer, but was significantly related with increased risk of cutaneous melanoma (Gln/Gln vs Lys/Lys: OR=1.15, 95%CI=1.02-1.29, p=0.023; dominant model: OR=1.09, 95%CI=1.01-1.18, p=0.036).
|
25169498 |
2014 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although an XPD haplotype was associated with melanoma, it did not contain the variant 751 Gln allele, which has been associated with melanoma in some previous studies.
|
17210993 |
2007 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest these two XPD nonsynonymous polymorphisms may be associated with skin cancer risk, especially for melanoma.
|
15941969 |
2005 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
There is a report that one of the polymorphic XPD alleles (exon 23 Lys), which is over-represented in the melanoma group, has reduced repair proficiency and we discuss the possibility that this is the causal change to the XPD gene that predisposes to melanoma.
|
11238179 |
2001 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
XPD variants may modify melanoma risk in subjects with specific host characteristics, such as older age, lack of dysplastic naevi or low tanning ability.
|
14735199 |
2004 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Epidemiological studies have assessed the association between excision repair cross-complementing group 2 (ERCC2) Lys751Gln and Asp312Asn polymorphisms and melanoma risk with conflicting results.
|
29768284 |
2018 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To establish if the XPD common variants Asp312Asn and Lys751Gln are associated with an increased melanoma or breast cancer risk we performed an association study based on genotyping 426 unselected patients with malignant melanoma (MM) and 1830 consecutive breast cancer cases and compared the results to 1262 geographically matched newborns, 621 adults from the region of Szczecin (unselected for age and cancer family history), 421 healthy adults age- and sex-matched with the melanoma cases and 511 healthy controls matched with the breast cancer patients from the region of Szczecin.
|
16685590 |
2006 |
melanoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This is the first meta-analysis suggesting that XPD/ERCC2 might represent a low-penetrance melanoma susceptibility gene.
|
19706646 |
2009 |
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
In this study, we examined Lys751Gln polymorphism at the XPD gene in 244 melanoma patients and 251 healthy individuals (as controls) from the south-eastern region of Sweden.
|
18575735 |
2008 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The current meta-analyses results suggest that the XPD gene, but not the EGF gene, has contributed to CM susceptibility, and XPD is a possible drug target.
|
25537294 |
2015 |
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
The results provide further evidence for a role of XPD in the etiology of melanoma.
|
16258177 |
2006 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results provide further evidence for a role of XPD in the etiology of melanoma.
|
16258177 |
2006 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We concluded that genetic variants of the XPD gene might serve as biomarkers for susceptibility to cutaneous melanoma.
|
17164380 |
2006 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The dependence of TFIIH-CAK on sequence-specific MITF and c-MYC constitutes a previously unrecognized mechanism feeding into super-enhancer-driven or other oncogenic transcriptional circuitries, which supports the concept of a transcription-directed therapeutic intervention in melanoma.
|
30651597 |
2019 |
melanoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|